Поиск патентов

05-01-2012 дата публикации

Bone-like prosthetic implants

Номер: US20120003185A1

Автор: Shai Meretzki

Принадлежит: Individual

A prosthetic implant comprising a biocompatible three-dimensional scaffold and at least two cell types selected from the group consisting of osteoblasts, osteoclasts, and endothelial cells or progenitors thereof.

Подробнее

Номер записи: 1

19-01-2012 дата публикации

Estrogen receptors and methods of use

Номер: US20120016109A1

Автор: Zhao Yi Wang

Принадлежит: CREIGHTON UNIVERSITY

The present invention provides isolated polypeptides having an amino acid sequence having at least 70% identity to SEQ ID NO:20, wherein the polypeptide has ER-α36 activity. The invention further provides methods for identifying agents that bind to such polypeptides, methods for detecting such polypeptides, and methods for altering the activity of such polypeptides. Also provided are antibodies that specifically bind to an amino acid sequence depicted at SEQ ID NO:1, or an immunogenic fragment thereof, and methods for making and using such antibodies.

Подробнее

Номер записи: 2

19-01-2012 дата публикации

Diastereoisomers of hypophosphorous acid derivatives

Номер: US20120016155A1

Автор: Chelliah Selvam, Francine Acher, Jean-Philippe Pin

Принадлежит: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

The invention relates to the diastereoisomers of hypophosphorous acid derivatives, having formula (I), wherein the phenyl group is substituted by one or several atoms or groups, occupying one or several positions on the phenyl ring, and a method for the separation thereof.

Подробнее

Номер записи: 3

26-01-2012 дата публикации

Thermosensitive hydrogel composition and method

Номер: US20120020932A1

Автор: Archit Sanghvi, Jian Q. Yao, Jizong Gao, Xiao Huang

Принадлежит: Zimmer Orthobiologics Inc

A hydrogel-forming composition is provided that comprises an extracellular matrix protein, hyaluronic acid, and a thermosensitive biocompatible polymer such as methylcellulose. The hydrogels can provide a therapeutic effect; further, the hydrogels may comprise an optional therapeutic agent such as cells or a pharmaceutical composition. The composition may be injected to an area in need of treatment by the therapeutic agent. The composition may form a gel at about 37° C., such that the gel maintains the therapeutic agent in the area of the body in need of such treatment.

Подробнее

Номер записи: 4

02-02-2012 дата публикации

Method of preparing lipid nanoparticles

Номер: US20120027825A1

Автор: Alyaa Adel Ramadan, Jean-Pierre Benoit, Olivier Thomas, Patrick Saulnier

Принадлежит: Institut National de la Sante et de la Recherche Medicale INSERM, Universite dAngers

The present invention relates to a useful method for preparing nanocapsules having a liquid lipid core and a solid shell and charged with at least one active agent having a hydrophilic character, said method comprising at least the steps consisting in: i) providing at least a first microemulsion having a water-in-oil character, stabilized by at least one lipophilic surfactant and containing in its hydrophilic phase at least one active agent having a hydrophilic character, providing at least a second microemulsion, separate from the first microemulsion, formulated by phase inversion of an emulsion and stabilized by at least one heat-sensitive, nonionic hydrophilic surfactant; iii) adding said first microemulsion to said second microemulsion under conditions propitious for the formation of a novel microemulsion architecture in which said hydrophilic active agent remains present in the hydrophilic phase of the first microemulsion; and iv) chill-hardening the mixture formed in the previous step, so as to obtain nanocapsules comprising said hydrophilic active agent and being formed from a lipid core, which is liquid at room temperature, and encapsulated in a film which is solid at room temperature. Further, the invention relates to nanocapsules which are able to be obtained by said method.

Подробнее

Номер записи: 5

02-02-2012 дата публикации

Whitefly Ecdysone Receptor Nucleic Acids, Polypeptides, and Uses Thereof

Номер: US20120028300A1

Автор: Dean Ervin Cress, Jianzhong Zhang, Subba Reddy Palli, Tarlochan Singh Dhadialla

Принадлежит: Intrexon Corp

The present invention relates to a novel isolated whitefly ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the whitefly ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene expression modulation system and methods for identifying molecules that modulate whitefly ecdysone receptor activity.

Подробнее

Номер записи: 6

09-02-2012 дата публикации

Dentifrice composition and method of use

Номер: US20120034282A1

Автор: Evangelia Arvanitidou, Joe Vazquez, Mary Horchos, Qing Claire He, Thomas Boyd, Ying Yang

Принадлежит: Colgate Palmolive Co

An exfoliating dentifrice composition is described that contains a plurality of granules and an orally acceptable vehicle. The granules include at least one polymeric binding agent. The composition includes at least one abrasive agent having an average particle diameter of 0.01 mm to 4 mm. Also included are methods of exfoliating an oral cavity soft tissue by use of the composition.

Подробнее

Номер записи: 7

01-03-2012 дата публикации

Composition and a method for producing contrast agent using the composition

Номер: US20120052011A1

Автор: Kouichi Kato, Satoshi Yuasa, Tatsuki Fukui

Принадлежит: Canon Inc

A composition including a hydrophilic dye having a sulfonate group and a hydrophobic solvent, wherein the composition includes at least one of a nicotinic acid derivative and a tiamine derivative, can form densely accumulated particles and the like since the composition includes a hydrophilic dye that is likely to dissolve in a hydrophobic solvent.

Подробнее

Номер записи: 8

08-03-2012 дата публикации

Anesthesia reversal methods and systems

Номер: US20120055481A1

Автор: Derek Jo Sakata, Dwayne R. Westenskow, Joseph A. Orr

Принадлежит: ANECARE LLC

An apparatus for reversing inhaled anesthesia, which may be configured to be positioned along a breathing circuit or anesthesia delivery circuit, includes an anesthesia removal component and a blood flow acceleration component. The blood flow acceleration component facilitates an increase in the ventilation of the individual without resulting in a significant decrease in the individual's P a CO 2 level and, thus, a decrease in the rate at which blood flows through the individual's brain. A method of reversing the effects of inhaled anesthesia includes increasing the rate of ventilation of an anesthetized individual while causing the individual to inhale gases with at least atmospheric amounts of CO 2 .

Подробнее

Номер записи: 9

15-03-2012 дата публикации

siRNA Targeting Apolipoprotein B (APOB)

Номер: US20120065250A1

Автор: Anastasia Khvorova, Angela Reynolds, Devin Leake, Stephen Scaringe, Steven Read, William Marshall

Принадлежит: Dharmacon Inc

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB.

Подробнее

Номер записи: 10

12-04-2012 дата публикации

Compositions comprising female germline stem cells and methods of use thereof

Номер: US20120087898A1

Автор: Jonathan Lee Tilly, Joshua Johnson

Принадлежит: General Hospital Corp

The present invention relates to female germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof.

Подробнее

Номер записи: 11

26-04-2012 дата публикации

Novel cellular factor-containing solution compositions

Номер: US20120101036A1

Автор: Catherine J. Trumpower, Charlotte A. Smith, Vivienne S. Marshall

Принадлежит: Stemnion LLC

The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.

Подробнее

Номер записи: 12

03-05-2012 дата публикации

Amphoteric liposomal compositions for cellular delivery of small rna molecules for use in rna interference

Номер: US20120107389A1

Автор: Arabinda Chaudhuri, Jayanta Bhattacharyya

Принадлежит: Individual

The present invention provides method and pharmaceutical composition for efficient delivery of siRNA (small interfering ribonucleic acids) into cultured mammalian cells. In addition, the present invention provides methods and compositions for knocking down the expression of a specific target gene by treating cells with the formulations comprising cationic amphiphile, a neutral colipid and a small RNA molecule. We demonstrate that our method delivers siRNA efficaciously into animal cells for the purpose of RNA interference. The area of medical science that is likely to benefit most from the present invention is RNAi therapeutics.

Подробнее

Номер записи: 13

03-05-2012 дата публикации

Anti bone-loss and anti attachment-loss effects of an oral composition

Номер: US20120107843A1

Автор: Emi Shimizu, Harsh M. Trivedi, Nicola C. Partridge, Tao Xu, Virginia Barnes, Wei Wang

Принадлежит: Colgate Palmolive Co

Methods for identifying compounds useful for treating diseases and conditions of the oral cavity are described herein.

Подробнее

Номер записи: 14

24-05-2012 дата публикации

Method of preparing pluripotent stem cells

Номер: US20120129256A1

Автор: Mariya A. Lagar'kova, Mariya V. Shutova, Sergey L. Kiselev

Принадлежит: OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "LABORATORIA KLETOCHNYKH TEKHNOLOGIY\

The invention relates to biotechnology, and particularly to the preparation of pluripotent stem cells. The method involves introduction into umbilical cord and placental stem cells of RNA with at least one sequence which ensures the transition of cells to the pluripotent state. The method enables to effectively prepare pluripotent stem cells from the cells of mammalian placenta and umbilical cord which have not yet acquired somatic mutations, which reduces the risk of oncogenesis and other adverse effects of reprogramming.

Подробнее

Номер записи: 15

07-06-2012 дата публикации

Targeted integration into the ppp1r12c locus

Номер: US20120142055A1

Автор: David Paschon, Fyodor Urnov, Philip D. Gregory, Phillip Tam, Russell DeKelver

Принадлежит: Sangamo Biosciences Inc

Disclosed herein are methods and compositions for targeted integration of an exogenous sequence into the human PPP1R12C locus, for example, for expression of a polypeptide of interest.

Подробнее

Номер записи: 16

21-06-2012 дата публикации

Chemical method for sexual sterilization and libido elimination in male mammals

Номер: US20120156188A1

Автор: Marcelo Vivacqua

Принадлежит: Individual

A chemical method for sexual sterilisation and libido suppression in male mammals is indicated to achieve the biological sterilisation of male mammals such as bovines, sheep, goats, equines, swine, dogs, cats and humans. The invention consists in a sterile aqueous solution containing an active sclerosing principle (lactic acid) and an enzyme (papain). The enzyme causes digestion of testicle tissue, intensifying the acid's necrosing effect and causing it to act faster and more efficiently. The association of these two active principles provokes an acute inflammatory reaction with a quick resolution characterised by fibrosing of the organ. This effect leads to the loss of the gametogenic and androgenic functions, and causes sterility and libido suppression, respectively. The biological sterilisation process can be easily carried out and does not require additional treatments, requiring less handling of the animals, with less stress and increased weight gain. The process is not painful either during or after administration, owing to the lesion of the testicle nerve endings at the moment of application, and to the fact that the greatest number of sensitive structures is located in the scrotal sac. The meat of thus treated cattle does not require for consumption a waiting period between application and slaughter, since the biological active principles can be easily metabolised by the animal organism. This method has already been successfully used in more than 3,000 animals, and is the only method available today in which naturally available biological active principles are used.

Подробнее

Номер записи: 17

21-06-2012 дата публикации

Treatment of menopause-associated symptoms

Номер: US20120157424A1

Автор: Earl E. Sands, John Brennan, Rex Horton, Zurab Bebia

Принадлежит: Besins Healthcare SA

Described are estradiol-containing pharmaceutical compositions and, and methods using the same to alleviate menopause-related symptoms, such as hot flushes, by topically administering estradiol at low effective doses.

Подробнее

Номер записи: 18

28-06-2012 дата публикации

Zona pellucida binding peptides, expression vectors, compositions, and methods for species-specific immunocontraception of animals

Номер: US20120164165A1

Автор: Henry J. Baker, Kent Van Kampen, Nancy Cox, Stephen Ditchkoff, Tatiana I. Samoylova

Принадлежит: AUBURN UNIVERSITY

Disclosed are methods, compositions, zona pellucida binding peptides and polypeptides, and expression vectors for use in species-specific immunocontraception of animals. The disclosed compositions may include immunogenic compositions or vaccines.

Подробнее

Номер записи: 19

05-07-2012 дата публикации

Mass spectrometric quantitation assay for metabolites of leflunomide

Номер: US20120171151A1

Автор: Karin O. Thomassian

Принадлежит: Individual

Methods are described for determining the amount of metabolites of leflunomide in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying teriflunomide in a sample.

Подробнее

Номер записи: 20

05-07-2012 дата публикации

Polypeptides of Botryosphaeria Rhodina

Номер: US20120171189A1

Автор: Kirk Matthew Schnorr, Lene Lange, Pernille Uldall Bolvig

Принадлежит: Novozymes AS

The invention relates to functional polypeptides secreted from Botryospaeria rhodina CBS 274.96.

Подробнее

Номер записи: 21

26-07-2012 дата публикации

Cyanocobalamin low viscosity aqueous formulations for intranasal delivery

Номер: US20120190640A1

Автор: Anthony P. Sileno, Peter C. Aprile, Steven C. Quay, Zenaida O. Go

Принадлежит: Par Pharmaceuticals Inc

A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering, intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin.

Подробнее

Номер записи: 22

09-08-2012 дата публикации

Methods and devices for the sustained release of multiple drugs

Номер: US20120202742A1

Автор: Eyal S. Ron, Robert S. Langer, William F. Crowley, Jr.

Принадлежит: General Hospital Corp, Massachusetts Institute of Technology

The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman.

Подробнее

Номер записи: 23

09-08-2012 дата публикации

Management of breakthrough bleeding in extended hormonal contraceptive regimens

Номер: US20120202779A1

Автор: Andreas Sachse

Принадлежит: Bayer Pharma AG

The present invention relates to a flexible extended use regimen for a hormonal contraceptive useful to manage bleeding problems associated with fixed extended use of hormonal contraceptives and to a pharmaceutical package containing the respective hormonal contraceptive.

Подробнее

Номер записи: 24

16-08-2012 дата публикации

Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers

Номер: US20120207771A1

Автор: Daniel J. O'shannessy, Elizabeth Brooke Somers, Luigi Grasso, Qimin Chao, Shanhong Wan

Принадлежит: Morphotek Inc

The present invention provides methods and kits for assessing whether a subject is afflicted with an FRα-expressing cancer, methods and kits for predicting the progression of ovarian cancer in a subject afflicted with an FRα-expressing cancer, methods and kits for assessing the level of risk that a subject will develop an FRα-expressing cancer, and methods of stratifying a subject with an FRα-expressing cancer into cancer therapy groups. The methods involve determining the level of folate receptor alpha (FRα) which is not bound to a cell in a sample derived from the subject and comparing this level with the level of FRα in a control sample.

Подробнее

Номер записи: 25

16-08-2012 дата публикации

Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles

Номер: US20120208754A1

Автор: Anna Muchnik, Houdin Dehnad, Pamela J. Fereira, Stephen A. Berry

Принадлежит: Intarcia Therapeutics Inc

This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1×10 −7 reciprocal second.

Подробнее

Номер записи: 26

23-08-2012 дата публикации

Generating induced pluripotent stem cells and progenitor cells from fibroblasts

Номер: US20120214236A1

Автор: Éva SZABÓ, Kausalia Vijayaragavan, Mickie Bhatia, Ruth Munoz Risueno, Shravanti Rampalli-Deshpande

Принадлежит: MCMASTER UNIVERSITY

The present disclosure provides a method of generating progenitor cells, such as hematopoietic or neural progenitor cells, from fibroblasts, such as dermal fibroblasts, comprising providing fibroblasts that express or are treated with a POU domain containing gene or protein and culturing the cells under conditions that allow production of progenitor cells, without traversing the pluripotent state. Also provided is a method of isolating a subpopulation of fibroblasts with reprogramming potential comprising providing fibroblasts that express an Oct-4-reporter and isolating cells that are positive for the reporter. Further provided is a method of generating reprogrammed fibroblast-derived induced pluripotent stem cells. Also provided are uses and assays of the cells produced by the methods of the disclosure.

Подробнее

Номер записи: 27

06-09-2012 дата публикации

Novel Cellular Factor-Containing Solution Compositions

Номер: US20120225815A1

Автор: Catherine J. Trumpower, Charlotte A. Smith, Vivienne S. Marshall

Принадлежит: Individual

The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.

Подробнее

Номер записи: 28

20-09-2012 дата публикации

Mammalian-type glycosylation in plants

Номер: US20120237972A1

Автор: Hendrik Jan Bosch, Hendrikus Antonius Cornelis Bakker

Принадлежит: Stichting Dienst Landbouwkundig Onderzoek DLO

The invention relates to the field of glycoprotein processing in transgenic plants used as cost efficient and contamination safe factories for the production of recombinant biopharmaceutical proteins or pharmaceutical compositions comprising these. The invention provides a plant comprising a functional mammalian enzyme providing N-glycan biosynthesis that is normally not present in plants, said plant additionally comprising at least a second mammalian protein or functional fragment thereof that is normally not present in plants.

Подробнее

Номер записи: 29

18-10-2012 дата публикации

Process for the preparation of drospirenone

Номер: US20120264723A1

Автор: Francesca Costantino, Roberto Lenna, Silvia Piuri

Принадлежит: Individual

A process is described for the preparation of drospirenone, a synthetic steroid with progestogenic, antimineralocorticoid and antiandrogenic activity, useful for preparing pharmaceutical compositions with contraceptive action; comprising the oxidation of 17α-(3-hydroxypropyl)-6β,7β,15β,16β-dimethylene-5β-androstane-3β,5,17β-triol.

Подробнее

Номер записи: 30

18-10-2012 дата публикации

Use of thiazolidinediones for the partial inhibition of androgen binding to aromatase

Номер: US20120264786A1

Автор: Donna Lin Tang Seto-Young, Leonid Poretsky

Принадлежит: BETH ISRAEL DEACONESS MEDICAL CENTER INC

A method for the treatment or prophylaxis of a disorder, wherein the disorder is affected by estrogen, comprising partially inhibiting aromatase activity or interfering with the binding of androgen to aromatase by administering a therapeutically effective amount of a thiazolidinedione to the patient. The use of rosiglitazone or pioglitazone to partially inhibit the binding of androgen to aromatase by at least 20% is preferred.

Подробнее

Номер записи: 31

18-10-2012 дата публикации

Salt forms of [R-(R,R)]-2-(4-flurorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid

Номер: US20120264934A1

Автор: Anthony Michael Campeta, Jason Albet Leonard, Joseph F. Krzyzaniak

Принадлежит: PFIZER INC

Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

Подробнее

Номер записи: 32

25-10-2012 дата публикации

siRNA Targeting Apoliprotein (APOB)

Номер: US20120270926A1

Автор: Anastasia Khvorova, Angela Reynolds, Devin Leake, Stephen Scaringe, Steven Read, William Marshall

Принадлежит: Dharmacon Inc

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB.

Подробнее

Номер записи: 33

01-11-2012 дата публикации

Cell surface coating with hyaluronic acid oligomer derivative

Номер: US20120277416A1

Автор: Alexander Tuzikov, Deborah Adella Blake, Eleanor Christine Williams, Elena Yurievna Korchagina, Nicola Lewell Carter, Nicolai Bovin, Stephen Michael Henry

Принадлежит: Kode Biotech Ltd

A method of localising reproduction assisting hyaluronic acid to reproductive cell surfaces by covalently linking it to lipids is disclosed.

Подробнее

Номер записи: 34

08-11-2012 дата публикации

Modified bovine somatotropin polypeptides and their uses

Номер: US20120283171A1

Автор: Anna-Maria A. Hays Putman

Принадлежит: Ambrx Inc

Modified bovine somatotropin polypeptides and uses thereof are provided.

Подробнее

Номер записи: 35

15-11-2012 дата публикации

Combinations of trospium and salivary stimulants for the treatment of overactive bladder

Номер: US20120289531A1

Автор: Kenneth L. Duchin, Mehdi Paborji, Roger S. Flugel, Wendy Jade Limayo HERNANDEZ

Принадлежит: Theravida Inc

Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of immediate release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of immediate release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of immediate release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.

Подробнее

Номер записи: 36

22-11-2012 дата публикации

Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug

Номер: US20120295855A1

Автор: Herbert T. Nagasawa, Jonathan F. Cohen

Принадлежит: Max International LLC, US Department of Veterans Affairs VA

The present invention relates to compositions and methods for reducing oxidative stress in a cell, increasing glutathione levels in a cell, increasing L-cysteine levels in a cell and reducing hepatocytotoxicity by contacting a cell with a sulfhydryl protected glutathione prodrug or a sulfhydryl protected cysteine prodrug.

Подробнее

Номер записи: 37

22-11-2012 дата публикации

Gene Therapy Using Transposon-Based Vectors

Номер: US20120297493A1

Автор: Frederick M. Enright, Richard Cooper, William C. Fioretti

Принадлежит: Louisiana State University and Agricultural and Mechanical College, TransGenRx Inc

Methods and compositions are presented for the administration of transposon-based vectors to an animal or human to provide gene therapy to the animal or human.

Подробнее

Номер записи: 38

13-12-2012 дата публикации

Neutralizing prolactin receptor antibodies and their therapeutic use

Номер: US20120315276A1

Автор: Axel Harrenga, Christiane Otto, Christoph Freiberg, Mark Trautwein, Sandra Bruder, Siegmund Wolf, Simone Greven

Принадлежит: Bayer Intellectual Property GmbH

The present invention is directed to the neutralizing prolactin receptor antibody 002-H08, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.

Подробнее

Номер записи: 39

20-12-2012 дата публикации

Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom

Номер: US20120318701A1

Автор: Samuel P. McManus, Sean M. Culbertson

Принадлежит: Nektar Therapeutics

The present invention provides conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates. Methods of making polymeric reagents and conjugates, as well as methods for administering conjugates and compositions, are also provided.

Подробнее

Номер записи: 40

20-12-2012 дата публикации

Anti-Rhesus D Recombinant Polyclonal Antibody and Methods of Manufacture

Номер: US20120322690A1

Автор: Anne Bondgaard Tolstrup, John Haurum, Søren Bregenholt Frederiksen, Søren Kofoed Rasmussen

Принадлежит: Symphogen AS

The invention relates to a method for manufacturing an anti-RhD recombinant polyclonal antibody composition (anti-RhD rpAb). The method comprises obtaining a collection of cells transfected with a library of anti-RhD antibody expression vectors, wherein each cell in the collection is capable of expressing from a VH and VL comprising nucleic acid segment, one member of the library, which encodes a distinct member of anti-RhD recombinant polyclonal antibody composition and is located at the same site in the genome of individual cells in said collection. The cells are cultured under suitable conditions for expression of the recombinant polyclonal antibody, which is obtained from the cells or culture supernatant. Nucleic acid segments encoding the anti-RhD rpAb are introduced into the cells by transfection with a library of vectors for site-specific integration. The method is suitable for manufacturing anti-RhD rpAb, thereby making available a superior replacement of plasma-derived prophylactic and therapeutic immunoglobulin products.

Подробнее

Номер записи: 41

27-12-2012 дата публикации

Method for obtaining biologically active recombinant human g-csf

Номер: US20120328560A1

Автор: Christian Scheckermann, Walter Hinderer

Принадлежит: BIOGENERIX GMBH

Provided is a method of obtaining biologically active recombinant human G-CSF from inclusion bodies, wherein the solubilization and refolding process can be performed at ambient temperature and the purification step comprises reversed phase chromatography (RP), in particular RP-HPLC. The G-CSF preparation so obtained is characterized by high purity and homogeneity.

Подробнее

Номер записи: 42

27-12-2012 дата публикации

Immunogenic lhrh compositions and methods relating thereto

Номер: US20120328639A1

Автор: Michael Kerin Mcnamara

Принадлежит: PFIZER INC

The present invention relates generally to an immunogenic LHRH composition and more particularly to an immunogenic LHRH composition comprising a LHRH C-terminal fragment of at least five amino acids. The present invention is useful, inter alia, as a prophylactic and/or therapeutic agent for the modification of fertility and behaviour patterns of animals, the achievement of livestock production gains such as increasing growth, decreasing feed conversion ratios or the control of unwanted organoleptic characteristics or the treatment of disorders of the reproductive organs.

Подробнее

Номер записи: 43

17-01-2013 дата публикации

Orally administered agent and an orally administered agent/supporting substrate complex

Номер: US20130017235A1

Автор: Eiji Nogami

Принадлежит: Lintec Corp

With an object of providing an orally administered agent (in particular a film-shaped orally administered agent) with which the ease and safety of taking the agent are improved, to attain this object, in an orally administered agent 1 b having one drug-containing layer 11 and two water-swellable gel-forming layers 12, the water-swellable gel-forming layers 12 are provided, either directly or via intermediate layers, on the both faces of the drug-containing layer 11.

Подробнее

Номер записи: 44

31-01-2013 дата публикации

Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies

Номер: US20130028881A1

Автор: Andrea Ballabio, Bernhard Schmidt, Kurt Von Figura, Maria Pia Cosma, Michael W. Heartlein, Thomas Dierks

Принадлежит: Shire Human Genetics Therapies Inc

This invention relates to methods and compositions for the diagnosis and treatment of Multiple Sulfatase Deficiency (MSD) as well as other sulfatase deficiencies. More specifically, the invention relates to isolated molecules that modulate post-translational modifications on sulfatases. Such modifications are essential for proper sulfatase function.

Подробнее

Номер записи: 45

31-01-2013 дата публикации

Composition and Manufacturing Processes of a Toxicity Free Botanical Drug for Curative Treatment of Chronic Diseases

Номер: US20130028993A1

Автор: Aditi Kumar, ASHOK KUMAR, Prakrati Kumar, Priti Kumar

Принадлежит: Individual

This invention discloses composition and manufacturing processes of a toxicity free botanical drug formulation for curative treatment of chronic diseases. It is manufactured from plants Crinum asiaticum and Crocus sativus. This drug was administered to human volunteers by oral and intranasal routes in effective amount for an effective time period. Effective amount and effective time of administration varies from one human volunteer to another depending upon age, body weight, length of disease, severity of disease, type of the disease. In vitro experiments show that this botanical drug causes proliferation and differentiation of stem cells.

Подробнее

Номер записи: 46

31-01-2013 дата публикации

Crosslinked human or animal tissue products and their methods of manufacture and use

Номер: US20130029915A1

Автор: Keith E. Myers, W. Jerry Mezger

Принадлежит: HARBOR MEDTECH Inc

Degradable bioprostheses made of collagen-based material having amine-based and ester-based crosslinks are provided, as are methods for their formation and use. Some embodiments of the present invention are directed towards a method of controlling the ratio of amine-based crosslinks to ester-based crosslinks within a collagen-based material to provide a tailorably crosslinked collagen-based material. Some embodiments provide a method of making a degradable bioprosthesis involving controlling crosslinking to afford a degradable bioprosthesis that is partially crosslinked. By controlling the ratio of amine-based to ester-based crosslinks, by controlling the level of crosslinking, or by controlling both of these features, degradable bioprostheses with tailored degradation rates can be synthesized. Some embodiments of degradable bioprostheses have degradation rates that are tailored to allow their use in particular medical applications. Some embodiments are directed towards methods of use degradable bioprostheses in wound healing, tissue repair, and tissue supplementation.

Подробнее

Номер записи: 47

07-02-2013 дата публикации

Mitochondrial enhancement of cells

Номер: US20130034527A1

Автор: Lowell L. Wood, Roderick A. Hyde

Принадлежит: SEARETE LLC

Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of stem cells. Certain embodiments disclosed herein include, but are not limited to, methods of modifying stem cells, or methods of administering modified stem cells to at least one biological tissue.

Подробнее

Номер записи: 48

07-02-2013 дата публикации

Modified melk peptides and vaccines containing the same

Номер: US20130034574A1

Автор: Ryuji Ohsawa, Sachiko Yoshimura, Takuya Tsunoda, Tomohisa Watanabe, Yusuke Nakamura

Принадлежит: ONCOTHERAPY SCIENCE INC

Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild type MELK epitope peptide and thus are suitable for use in the context of cancer immunotherapy or endometriosis immunotherapy, more particularly cancer or endometriosis vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical substances and compositions of this invention find particular utility in the treatment of cancers, tumors, and endometriosis.

Подробнее

Номер записи: 49

07-02-2013 дата публикации

Transient immortalization

Номер: US20130035287A1

Автор: Anne Kuhn, Jan-Heiner Küpper, Mirella Meyer-Ficca, Ralph Meyer

Принадлежит: Heart Biosystems GmbH

The invention relates to a method for transiently immortalizing cells according to which immortalization proteins are introduced into the cells from outside. The invention also relates to a method for producing cells according to which organ-related cells are transiently immortalized by the exogenous supply of immortalization proteins and are remortalized after their expansion. The invention further relates to the cells produced according to the inventive method, to the use of said cells for producing a transplant and to the immortalization proteins used in the method.

Подробнее

Номер записи: 50

14-02-2013 дата публикации

Novel Cytokine Containing Compositions

Номер: US20130040880A1

Автор: Catherine J. Trumpower, Charlotte A. Smith, George L. Sing, Linda O. Palladino, Vivienne S. Marshall

Принадлежит: Stemnion LLC

The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.

Подробнее

Номер записи: 51

21-02-2013 дата публикации

Methods and apparatus for determining formulation orientation of multi-layered pharmaceutical dosage forms

Номер: US20130043612A1

Автор: Johan H. Geerke, Steven F. Stone

Принадлежит: Alza Corp

Rapid and accurate determination of the formulation orientation of multi-layer capsule-shaped tablets with respect to different internal formulation layers proximate to the opposite narrow and rounded ends of the tablets is required. By including an appropriate color scheme in multi-layer osmotic tablets, detection of the formulation orientation is achieved by detecting the color at a spot location on a side of the tablet corresponding to one or another formulation layer or to one or another interface of two formulation layers depending on the formulation orientation of the tablet.

Подробнее

Номер записи: 52

07-03-2013 дата публикации

Induced pluripotent stem cells produced with oct3/4, klf and sox

Номер: US20130059386A1

Автор: Kazutoshi Takahashi, Keisuke Okita, Shinya Yamanaka

Принадлежит: KYOTO UNIVERSITY

The present invention relates to a nuclear reprogramming factor having an action of reprogramming a differentiated somatic cell to derive an induced pluripotent stem (iPS) cell. The present invention also relates to the aforementioned iPS cells, methods of generating and maintaining iPS cells, and methods of using iPS cells, including screening and testing methods as well as methods of stem cell therapy. The present invention also relates to somatic cells derived by inducing differentiation of the aforementioned iPS cells.

Подробнее

Номер записи: 53

07-03-2013 дата публикации

Novel methods for the preparation of p2x7r antagonists

Номер: US20130060047A1

Автор: Michael Bos

Принадлежит: Affectis Pharmaceuticals AG

Disclosed are novel methods for the synthesis of N-substituted indol-3-yl-alkylamide compounds which act as P2X7R antagonists, said methods involving the rearrangement of an oxime intermediate.

Подробнее

Номер записи: 54

14-03-2013 дата публикации

Pharmaceutical formulations

Номер: US20130064888A1

Автор: Dafna Arieli, Roey Solomonovich

Принадлежит: Individual

The present invention provides a pharmaceutical dosage form in the form of a tablet comprising: (a) a compressed inert core, (b) an optional subcoat over the compressed inert core, (c) a drug layer over the compressed core (a) or optional subcoat (b) comprising a drug having a water solubility at 25° C. of about 100 mg/l or less, a coating polymer and optionally a surfactant, and (d) optionally one or more layers coating the drug layer. The present invention also provides a process of making the same.

Подробнее

Номер записи: 55

21-03-2013 дата публикации

Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases

Номер: US20130072511A1

Автор: Charles L. Sawyers, Chris Tran, John Wongvipat, Michael E. Jung, Samedy Ouk

Принадлежит: UNIVERSITY OF CALIFORNIA

Described herein, inter alia, are compounds useful for the prevention or treatment of hyperproliferative diseases or disorders.

Подробнее

Номер записи: 56

04-04-2013 дата публикации

Compositions and methods for platelet enriched fibrin constructs

Номер: US20130084310A1

Автор: Brooks J. Story, Douglas A. Fifolt, Gregory R. Whittaker, Mehmet Z. Sengun, William Parrish

Принадлежит: DePuy Mitek LLC

Compositions and methods are provided for tissue constructs that promote wound healing. The composition comprises a dimensionally stable fibrin construct for local administration to a wound site or region. In one embodiment, the fibrin construct is a wound healing composition, including components that promote wound healing, such as platelets, growth factors, white blood cells and fibrin clots. In another embodiment, the tissue treatment composition includes (i) aggregated fibrin, (ii) blood cells, and (iii) optionally, growth factors and/or other proteins.

Подробнее

Номер записи: 57

25-04-2013 дата публикации

Method For Restoring Alveolar Bone Via Transplant of a Regenerated Tooth Unit

Номер: US20130101951A1

Автор: Kazuhisa Nakao, Masamitsu Oshima, Takashi Tsuji

Принадлежит: Organ Technologies Inc

The object of the present invention is to provide a method for restoring the alveolar bone of a mammal with a missing tooth. The present invention provides a method for restoring the alveolar bone in a mammal with a missing tooth comprising a step of transplanting a regenerated tooth unit to the said missing site. The regenerated tooth unit is characterized in that it has a periodontal tissue portion in addition to a tooth crown portion.

Подробнее

Номер записи: 58

02-05-2013 дата публикации

Compositions for the treatment of gynaecological disorders

Номер: US20130108717A1

Автор: Stefano Togni

Принадлежит: Indena SpA

The present invention relates to a combination of a rhatany extract, 18β-glycyrrhetic acid, in free form and in complexes with phospholipids, and Zanthoxylum bungeanum extract, for the topical treatment of gynaecological disorders, especially vulvovaginal infections.

Подробнее

Номер записи: 59

09-05-2013 дата публикации

Use of aromatase inhibitors for synchronizing ovulation, inducing superovulation or double ovulation and improving twinning and fertility in a mammal

Номер: US20130116177A1

Автор: Gregg Adams, Roger Pierson

Принадлежит: UNIVERSITY OF SASKATCHEWAN

Described herein are methods for synchronizing ovulation in a herd, inducing superovulation in a single animal, and improving frequency of successful implantation and development of fertilized ova.

Подробнее

Номер записи: 60

16-05-2013 дата публикации

Bioassay for gene silencing constructs

Номер: US20130125260A1

Автор: Ana M. Bailey, Charles Niblett

Принадлежит: Venganza Inc

The invention provides constructs and methods of screening for constructs useful in conferring resistance in plants to pests by gene silencing. The invention also provides pest-resistant plants transformed with the present constructs. One screening method of the invention comprises the steps of: selecting at least one pest target nucleotide sequence, producing a plurality of dsRNA test agents that target the pest target nucleotide sequence, testing and scoring the plurality of dsRNA test agents for toxicity to the pest, and producing a silencing construct based on a superior-scoring test agent.

Подробнее

Номер записи: 61

23-05-2013 дата публикации

Human Stem Cell Materials and Methods

Номер: US20130129696A1

Автор: Eliezer Huberman, Yong Zhao

Принадлежит: Individual

Monocyte derived adult stem cells (MDSCs) isolated from peripheral blood of mammals is provided, along with pharmaceutical compositions containing an MDSC, kits containing a pharmaceutical composition, and methods of preparing, propagating and using MDSCs or differentiated derivatives thereof The uses of these biological materials include methods of treating disorders or diseases, as well as methods of ameliorating a symptom associated with any such disorder or disease.

Подробнее

Номер записи: 62

23-05-2013 дата публикации

Peptide having cell membrane penetrating activity

Номер: US20130129726A1

Автор: Kyunglim Lee

Принадлежит: Industry Collaboration Foundation of Ewha University

Provided are transmembrane complexes that contain a protein transduction domain (PTD) from the N-terminus of IgE-dependent histamine-releasing factor (HRF) and a target substance that is to be delivered into a cell. Also provided are nucleic acid molecules encoding the transmembrane complex, and methods of delivering the target substance into a cell interior by contacting the transmembrane complex with a cell. Also provided are transfection kits containing the PTD and the target substance.

Подробнее

Номер записи: 63

23-05-2013 дата публикации

Natural combination hormone replacement formulations and therapies

Номер: US20130129818A1

Автор: Brian A. Bernick, Janice Louise Cacace, Julia M. Amadio, Neda Irani, Peter H.R. Persicaner

Принадлежит: TherapeuticsMD Inc

Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.

Подробнее

Номер записи: 64

13-06-2013 дата публикации

Substituted 16,17-annellated steroid compounds for use in womens health

Номер: US20130150337A1

Автор: Antonius Gerardus Hendrikus Ederveen, Fredericus Antonius Dijcks, Hubert Jan Jozef Loozen, Samira Addo

Принадлежит: MSD Oss BV

The present invention relates to substituted steroid compounds having the formula Wherein R 1 is H or halogen; R 2 is H, (1C-4C)alkyl, (1C-4C)acyl, glucuronyl or sulfamoyl; R 3 is H or halogen; R 4 is H, (1C-4C)alkyl, (2C-4C)alkenyl or (2C-4C)alkynyl; R 5 is methyl or ethyl; R 6 is H or methyl; R 7 is H or methyl; R 8 is H or acyl for use in the treatment and prevention of endometriosis, for contraception, for hormonal therapy in perimenopausal and post-menopausal women, for the treatment of osteoporosis and for the treatment uterine fibroids and other menstrual-related disorders, such as dysfunctional uterine bleeding.

Подробнее

Номер записи: 65

20-06-2013 дата публикации

Hsp70 fusion protein conjugates and uses thereof

Номер: US20130156694A1

Автор: Alex Nivorozhkin, Alexander V. ZEMLYANOI, Mikhail Viktorovich Shorokhov, Sergei B. ONIKIENKO, Valery Aleksandrovich Chereshnev, Vladimir Ivanovich Pereguda

Принадлежит: Alternative Innovative Tech LLC

The present invention relates to novel therapies that utilize HSP70 fusion proteins for the treatment of disorders or conditions regulated by HSP70.

Подробнее

Номер записи: 66

27-06-2013 дата публикации

Imaging and evaluating embryos, oocytes, and stem cells

Номер: US20130162795A1

Автор: Barry Behr, Connie C. Wong, Kevin E. Loewke, Renee A. Reijo-Pera, Thomas M. Baer

Принадлежит: Leland Stanford Junior University

Methods, compositions and kits for determining the developmental potential of one or more embryos or pluripotent cells and/or the presence of chromosomal abnormalities in one or more embryos or pluripotent cells are provided. These methods, compositions and kits find use in identifying embryos and oocytes in vitro that are most useful in treating infertility in humans.

Подробнее

Номер записи: 67

04-07-2013 дата публикации

Immunomodulatory Compounds for the Restoration of Vitamin D Sensitivity in Vitamin D Resistant Tumor Cells

Номер: US20130171196A1

Автор: Angus George Dalgleish, Carole Brosseau, Christine Galustian, Justin Blake Bartlett, Kay Winifred Colston

Принадлежит: Celgene Corp

Provided herein are methods of restoring vitamin D sensitivity in tumor cells that are vitamin D resistant. Also provided are methods of treating, preventing or managing cancer using an immunomodulatory compound in combination with a vitamin D agent. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed.

Подробнее

Номер записи: 68

04-07-2013 дата публикации

Gene therapy for sulfatase deficiency

Номер: US20130172403A1

Автор: Andrea Ballabio, Bernhard Schmidt, Kurt Von Figura, Maria Pia Cosma, Michael W. Heartlein, Thomas Dierks

Принадлежит: Shire Human Genetics Therapies Inc

This invention relates to methods and compositions for the diagnosis and treatment of Multiple Sulfatase Deficiency (MSD) as well as other sulfatase deficiencies. More specifically, the invention relates to isolated molecules that modulate post-translational modifications on sulfatases. Such modifications are essential for proper sulfatase function.

Подробнее

Номер записи: 69

01-08-2013 дата публикации

ENHANCEMENT OF siRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND

Номер: US20130196434A1

Автор: Haripriya Addepalli, Martin Maier, Muthiah Manoharan

Принадлежит: Alnylam Pharmaceuticals Inc

One aspect of the present invention relates to a double stranded nucleic acid useful as an siRNA, that has a sense strand and an antisense strand relative to a target nucleic acid, where the sense strand contains one or more modified nucleobases, or one or more mismatch base pairings with the antisense strand. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one nucleoside comprising a non-natural nucleobase. Another aspect of the invention relates to a method of gene silencing, comprising administering to a mammal in need thereof a therapeutically effective amount of a double-stranded oligonucleotides containing a sense strand and an antisense strand, where the sense strand contains one or more modified nucleobases, or one or more mismatch base pairings with the antisense strand.

Подробнее

Номер записи: 70

15-08-2013 дата публикации

Expansion Of Stem/Progenitor Cells By Inhibition Of Enzymatic Reactions Catalyzed By The Sir2 Family Of Enzymes

Номер: US20130209414A1

Автор: Tony Peled

Принадлежит: Gamida Cell Ltd

Provided are ex vivo and in vivo methods of expanding renewable stem cells using agents capable of down-regulating Sir2 protein activity and/or expression, expanded populations of renewable stem cells, and uses thereof.

Подробнее

Номер записи: 71

15-08-2013 дата публикации

siRNA Targeting Myeloid Differentiation Primary Response Gene (88) (MYD88)

Номер: US20130210676A1

Автор: Anastasia Khvorova, Angela Reynolds, Devin Leake, Stephen Scaringe, Steven Read, William Marshall

Принадлежит: Dharmacon Inc

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MYD88.

Подробнее

Номер записи: 72

19-09-2013 дата публикации

Combination therapy for chemoresistant cancers

Номер: US20130244950A1

Автор: Han Win Tun, John A. Copland, Iii, Laura Ann Marlow, Simon James Cooper

Принадлежит: Celgene Corp

Methods of treating, preventing or managing triple negative breast cancer (TNBC) or clear cell renal cell carcinoma (ccRCC) are disclosed. The methods encompass the administration of an HDAC inhibitor romidepsin in combination with a cytidine analog. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed.

Подробнее

Номер записи: 73

03-10-2013 дата публикации

Functionalized Water-Soluble Polyphosphazenes and Uses Thereof as Modifiers of Biological Agents

Номер: US20130261194A1

Автор: Alexander K. Andrianov

Принадлежит: Individual

A polyphosphazene polymer which includes hydrophilic side groups and interacting side groups which are capable of bonding with a biological agent of interest. The bonding may be by non-covalent bonding.

Подробнее

Номер записи: 74

10-10-2013 дата публикации

Method of determining risk of scoliosis

Номер: US20130266966A1

Автор: Alain Moreau

Принадлежит: CHU SAINTE-JUSTINE

A method for determining the risk for developing a scoliosis comprising monitoring osteopontin (OPN) expression in a sample from a subject over time; wherein an OPN expression that increases in the subject sample over time is indicative that the subject is at risk for developing a scoliosis.

Подробнее

Номер записи: 75

17-10-2013 дата публикации

Neutralizing prolactin receptor antibodies and their therapeutic use

Номер: US20130272968A1

Автор: Andrea Eicker, Andreas Wilmen, Axel Harrenga, Christiane Otto, Christoph Freiberg, Mark Trautwein, Sandra Bruder, Siegmund Wolf, Simone Greven

Принадлежит: Bayer Intellectual Property GmbH

The present invention is directed to the neutralizing prolactin receptor antibody 006-H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.

Подробнее

Номер записи: 76

24-10-2013 дата публикации

Jnk inhibitors for the treatment of endometriosis

Номер: US20130281447A1

Автор: Selvaraj Nataraja, Stephen S. Palmer

Принадлежит: MERCK SERONO SA

This invention relates to a method of treating and/or preventing endometriosis comprising administering a JNK inhibitor. The JNK inhibitor can also be administered combined with a hormonal suppressor. The invention further relates to the treatment of endometriosis.

Подробнее

Номер записи: 77

07-11-2013 дата публикации

Polypeptides Having Phytase Activity and Polynucleotides Encoding Same

Номер: US20130298267A1

Автор: Carsten Sjoeholm, Lars Kobberoee Skov, Leonardo De Maria, Soeren Flensted Lassen

Принадлежит: Novozymes AS

The present invention relates to polypeptides having phytase activity. These polypeptides have an amino acid sequence which has at least 70% identity to either of three phytases derived from the bacterium Buttiauxella , and which comprises at least one of the following amino acids at the position indicated: 119N, 120L, and/or 121E. These phytases have an improved specific activity. Additional specific amino acid substitutions are also disclosed which characterize and distinguish additional phytases of the invention having improved properties such as temperature and/or pH stability, pH activity profile, temperature activity profile, substrate profile, improved performance in animal feed in vitro or in vivo. The invention also relates to isolated polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.

Подробнее

Номер записи: 78

26-12-2013 дата публикации

Low flush niacin formulation

Номер: US20130344144A1

Автор: Eugenio Cefali, Jose G. Rocca, Yucun Zhu

Принадлежит: AbbVie Inc

The invention relates to an extended-release matrix formulation capable of being directly compressed into tablets comprising niacin, a release-retarding agent, and other excipients. The resulting tablets of the invention demonstrate favorable release characteristics and a reduction in the severity, duration and incidences of cutaneous flushing commonly associated with niacin treatment.

Подробнее

Номер записи: 79

02-01-2014 дата публикации

Salt forms of [R-(R,R)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid

Номер: US20140005384A1

Автор: Anthony Michael Campeta, Jason Albert Leonard, Joseph Francis Krzyzaniak

Принадлежит: PFIZER INC

Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

Подробнее

Номер записи: 80

16-01-2014 дата публикации

Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus

Номер: US20140017314A1

Автор: Dan E. Dobry, Dana M. Settell, Heather L. M. Diebele, Ken R. Spence, Roderick J. Ray, Ronald A. Beyerinck

Принадлежит: Bend Research Inc

Conventional spray-drying methods are improved by incorporation of a pressure nozzle and a diffuser plate to improve the flow of drying gas and a drying chamber extension to increase drying time, such improvements leading to the formation of homogeneous solid dispersions of drugs in concentration-enhancing polymers.

Подробнее

Номер записи: 81

20-02-2014 дата публикации

Stem cell packaging and shipping

Номер: US20140051165A1

Автор: Dongming Sun, Kam Sze Kent TSANG, Robert FLEISCHAKER, Wise Young

Принадлежит: Stemcyte Inc

This invention concerns methods of packaging and shipping stem cells. Also disclosed are related package products.

Подробнее

Номер записи: 82

27-02-2014 дата публикации

Process for delivering encapsulated neutral bioimaging molecules, complex, and process thereof

Номер: US20140056818A1

Автор: Dhiraj Bhatia, Yamuna Krishnan

Принадлежит: NATIONAL CENTRE FOR BIOLOGICAL SCIENCES

The present disclosure relates to delivering neutral bioimaging molecules encapsulated within icosahedral DNA capsules in vivo and in vitro. The present disclosure also discloses the entrapment of neutral bioimaging molecules like FITC dextran within the cavity of a DNA polyhedron without any molecular recognition or chemical conjugation between host (DNA icosahedron) and cargo (like FITC Dextran). This DNA polyhedron is structurally well defined and shows high encapsulation efficiency. The present disclosure also relates to complex formed due to the encapsulation of neutral bioimaging agents within icosahedral DNA capsules.

Подробнее

Номер записи: 83

13-03-2014 дата публикации

OPTIMIZED Fc VARIANTS

Номер: US20140073768A1

Автор: Gregory Alan Lazar, John Desjarlais, Jost Vielmetter, Omid Vafa, Robert Hayes, Sher Bahadur Karki, Wei Dang

Принадлежит: Xencor Inc

The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.

Подробнее

Номер записи: 84

20-03-2014 дата публикации

Maternal sialic acid supplementation

Номер: US20140080767A1

Автор: Christopher M. Butt, John P. Zimmer

Принадлежит: DSM IP ASSETS BV

The invention provides methods and compositions for improving fetal and child health and development through nutritional supplementation with, for example, sialic acid. Sialic acid can be provided to a female before, during and/or after pregnancy to improve the health and development of a fetus and/or child. The sialic acid can be in a variety of forms in the supplements.

Подробнее

Номер записи: 85

03-04-2014 дата публикации

Outer layer having entanglement of hydrophobic polymer host and hydrophilic polymer guest

Номер: US20140093717A1

Автор: Guy Beauregard, Min Zhang, Susan P. James

Принадлежит: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION

An outer layer having an entanglement comprising an intermingling of cloaked hydrophilic guest and a hydrophobic polymer host, wherein molecules of the guest have been crosslinked with each other. Under certain circumstances, using complexes of the guest may be desirable or even necessary. The intermingling of the guest and host includes a physical tangling, whether it also comprises crosslinking by primary bonding (e.g., chemical/covalent bonding) there-between. Also a method of producing an outer layer having such an entanglement, including the steps of: temporarily cloaking at least a portion of the hydrophilic groups of the guest; intermingling at least a portion of the cloaked groups with a porous polymeric structure by diffusing the guest with cloaked groups into at least a portion of the structure's pores; within the pores, crosslinking at least a portion of the molecules of the guest with the guest; and removing the cloaking. Cloaking may be performed by silylation or acylation. Intermingling may be performed by producing a mixture of guest and host (whether in solution, powdered, granular, etc., form); next, a crosslinking of the guest with itself is performed; then, the mixture is molded into the outer layer.

Подробнее

Номер записи: 86

03-04-2014 дата публикации

Aromatic-cationic peptides and uses of same

Номер: US20140093897A1

Автор: Alexander V. Birk, D. Travis Wilson, Hazel H. Szeto

Принадлежит: CORNELL UNIVERSITY, Stealth Biotherapeutics Corp

The present disclosure provides aromatic-cationic peptide compositions and methods of using the same. The methods comprise use of the peptides in electron transport and electrical conductance.

Подробнее

Номер записи: 87

03-04-2014 дата публикации

Natural combination hormone replacement formulations and therapies

Номер: US20140094440A1

Автор: Brian A. Bernick, Janice Louise Cacace, Julia M. Amadio, Neda Irani, Peter H.R. Persicaner

Принадлежит: TherapeuticsMD Inc

Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.

Подробнее

Номер записи: 88

10-04-2014 дата публикации

Natural combination hormone replacement formulations and therapies

Номер: US20140100205A1

Автор: Brian A. Bernick, Janice Louise Cacace, Julia M. Amadio, Neda Irani, Peter H.R. Persicaner

Принадлежит: TherapeuticsMD Inc

Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.

Подробнее

Номер записи: 89

07-01-2021 дата публикации

ALCOHOL-BASED COMPOSITIONS AND USES THEREOF

Номер: US20210000760A1

Автор: Afsahi Vince, Rotunda Adam M.

Принадлежит:

This disclosure relates to a method of reducing a fat deposit comprising injecting an alcohol-containing pharmaceutical composition into the fat deposit. The method may be effective in improving the appearance of or reducing the weight or volume of the fat deposit. 1. A method of reducing a fat deposit comprising injecting a pharmaceutical composition into the fat deposit , wherein the pharmaceutical composition comprises an alcohol , wherein the method is effective in reducing the weight or volume of the fat deposit.2. The method of claim 1 , wherein the alcohol is polidocanol.3. The method of claim 1 , wherein the alcohol comprises ethanol.4. The method of claim 3 , wherein the pharmaceutical composition further comprises polidocanol.5. The method of claim 1 , further comprising a steroid.6. The method of claim 1 , further comprising a bile salt.7. The method of claim 1 , further comprising a detergent.8. The method of claim 1 , further comprising a dermal filler.9. The method of claim 1 , further comprising a neurotoxin.10. The method of claim 1 , wherein the fat deposit is a lipoma.11. The method of claim 1 , wherein the fat deposit is cellulite.12. The method of claim 1 , wherein the fat deposit is on a human head.13. The method of claim 1 , wherein the fat deposit is on a human neck.14. The method of claim 1 , wherein the fat deposit is on a human torso.15. The method of claim 1 , wherein the fat deposit is on a human buttock.16. The method of claim 1 , wherein the fat deposit is on a human leg.17. The method of claim 1 , wherein the fat deposit is on a human foot.18. The method of claim 1 , wherein the fat deposit is on a human arm.19. The method of claim 1 , wherein the fat deposit is on a human hand.20. The method of claim 1 , wherein on a single day claim 1 , about 1 mg to about 20 mg of the pharmaceutical composition claim 1 , per cmof fat deposit claim 1 , is injected into the fat deposit. This application is a continuation in part of U.S. patent ...

Подробнее

Номер записи: 90

04-01-2018 дата публикации

Pharmaceutical composition for the treatment of mycosis

Номер: US20180000783A1

Автор: Alessandra CAPEZZONE DE JOANNON, Claudio Milanese, Luca Donati, Serena Tongiani

Принадлежит: Aziende Chimiche Riunite Angelini Francesco ACRAF SpA

The present invention relates to a pharmaceutical composition comprising a combination of benzydamine and an antimycotic active ingredient, said combination having a synergistic effect in the treatment of mycosis.

Подробнее

Номер записи: 91

03-01-2019 дата публикации

ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF

Номер: US20190000812A1

Автор: GOTTELAND Jean-Pierre, Jorand-Lebrun Catherine, Loumaye Ernest, PAGE Patrick Naxos, POHL Oliver, POMEL Vincent, Quattropani Anna, Schwarz Matthias

Принадлежит:

The invention provides pharmaceutical compositions comprising a compound of formula (I) or (II) and an additional therapeutic agent Also provided is the HCI salt and crystalline form of the compound of formula (I). The compounds inhibit the prostaglandin F receptor (PGF2alpha) and thus useful in the treatment of disorders such as preterm labor at the early gestational stage. 3. The pharmaceutical composition of or , wherein said additional therapeutic agent is an additional tocolytic agent.4. The pharmaceutical composition of any one of - , wherein said pharmaceutical composition comprises one or more excipients.5. The pharmaceutical composition of any one of - , wherein said compound has a purity of at least 90% , 91% , 92% , 93% , 94% , 95% , 96% , 97% , 98% , 99% , or 99.9%.6. The pharmaceutical composition of claim 5 , wherein said purity is ascertained by high pressure liquid chromatography (HPLC).7. The pharmaceutical composition of claim 5 , wherein said purity is ascertained by NMR spectroscopy.8. The pharmaceutical composition of any one of - claim 5 , wherein said compound or pharmaceutical composition is formulated for oral administration to a subject.9. The pharmaceutical composition of any one of - claim 5 , wherein said compound or pharmaceutical composition is a tablet claim 5 , capsule claim 5 , gel cap claim 5 , powder claim 5 , liquid solution claim 5 , or liquid suspension.10. The pharmaceutical composition of any one of - claim 5 , wherein said compound or pharmaceutical composition is formulated for intravenous administration to a subject.11. The pharmaceutical composition of any one of - claim 5 , wherein said pharmaceutical composition comprises an oxytocin receptor antagonist.12. The pharmaceutical composition of claim 11 , wherein said oxytocin receptor antagonist is selected form the group consisting of atosiban claim 11 , retosiban claim 11 , barusiban claim 11 , epelsiban claim 11 , and nolasiban.13. The pharmaceutical composition of any ...

Подробнее

Номер записи: 92

07-01-2016 дата публикации

Thermosensitive hydrogel collagenase formulations

Номер: US20160000890A1

Автор: Bo Yu, Thomas L. Wegman

Принадлежит: Biospecifics Technologies LLC

It is an object of the present disclosure to provide a formulation for injectable and topical collagenase, which will have extended residence time for the drug at the therapeutic targeted area for the indication being treated. It is a further object of the disclosure to provide a slow release formulation for collagenase, which is compatible with the active ingredient and does not adversely affect its activity. Still a further object of the disclosure is to provide an injectable formulation for collagenase which can be effectively administered to a patient with a small size needle without exhibiting pre-gelation, which would interfere with the ability to deliver the required dose for treatment. Still a further object of the disclosure is to provide a water-based topical formulation for collagenase which will be more compatible with other topically used medications to achieve better results.

Подробнее

Номер записи: 93

03-01-2019 дата публикации

USE OF BOTULINUM NEUROTOXIN IN THE TREATMENT OF SIALORRHEA

Номер: US20190000938A1

Автор: Althaus Michael, CSIKOS Janos, KRÜER Markus, PULTE Irena, WEGENER Nico

Принадлежит:

This invention relates to improved uses of botulinum neurotoxins in the treatment of sialorrhea or diseases or conditions relating to increased saliva production. In particular are botulinum neurotoxins disclosed which are administered into parotid and submandibular glands in a dose ratio between 1.45 to 1 and 1.7 to 1. 1. A method for treating a disease or condition associated with sialorrhea or increased saliva production in a patient , the method comprising administering a therapeutically effective amount of a botulinum neurotoxin by injection into the parotid glands and submandibular glands of the patient , and wherein the ratio between the amount of the botulinum neurotoxin administered into each of the parotid glands and each of the submandibular glands is between 1.45 to 1 and 1.7 to 1.2. The method according to claim 1 , wherein the total dose of said botulinum neurotoxin administered into the parotid glands and submandibular glands is between 70 U and 110 U.3. The method according to claim 1 , wherein said botulinum neurotoxin is administered in an aqueous composition having a botulinum neurotoxin concentration in the range between 45 and of 55 U/mL.4. The method according to claim 1 , wherein said botulinum neurotoxin is administered in 0.3 to 0.5 mL per injection site into the submandibular glands and in 0.5 to 0.7 mL per injection site into the parotid glands.5. The method according to claim 1 , wherein said botulinum neurotoxin is injected into one site of each submandibular gland and/or into one site of each parotid gland.6. The method according to claim 1 , wherein the botulinum neurotoxin is injected into the parotid glands and submandibular glands using ultrasound guidance or without using ultrasound guidance.7. The method according to claim 1 , wherein the botulinum neurotoxin is administered into the parotid glands and submandibular glands in at least two consecutive treatment cycles claim 1 , optionally in at least 2 claim 1 , at least 3 claim 1 ...

Подробнее

Номер записи: 94

03-01-2019 дата публикации

TRIPARTITE MODULATORS OF ENDOSOMAL G PROTEIN-COUPLED RECEPTORS

Номер: US20190000981A1

Автор: Bunnett Nigel W., Cole Derek, Hicks Gareth, Hirst Gavin, Porter Christopher J.H., SHIRAI Junya

Принадлежит: Takeda Pharmaceutical Company Limited

The present invention relates to tripartite compounds comprising a modulator moiety for endosomal G protein-coupled receptors like neurokinin-1 receptor, a linker and a lipid anchor suitable for anchoring the tripartite compound into a plasma membrane. The present invention also relates to a prodrug and a pharmaceutical composition comprising the tripartite compound and the use of the tripartite compound for the treatment of a disease or disorder mediated by endosomal G protein-coupled receptors signalling like NKR signalling. 3. The tripartite compound according to claim 1 , wherein the lipid anchor partitions into lipid membranes that are insoluble in non-ionic detergent at 4° C.; or a pharmaceutically acceptable salt thereof.13. A prodrug of the tripartite compound according to .14. A composition comprising the tripartite compound according to claim 1 , or a prodrug thereof.1529.-. (canceled)30. A pharmaceutical composition comprising a therapeutically effective amount of the tripartite compound according to claim 1 , or a pharmaceutically acceptable salt or prodrug thereof claim 1 , and at least one pharmaceutically acceptable carrier or diluent.31. A method of preventing and/or treating a disease or disorder that is affected by a tachykinin receptor antagonist claim 1 , comprising administering to a patient in need thereof an effective amount of the tripartite compound of or a pharmaceutically acceptable salt or prodrug thereof.32. A method of preventing and/or treating a disease or disorder that is mediated by endosomal NKiR signaling claim 1 , comprising administering to a patient in need thereof an effective amount of the tripartite compound of or a pharmaceutically acceptable salt or prodrug thereof.33. The method of claim 32 , wherein the disease or disorder mediated by endosomal NKiR signaling is selected from the group consisting of chemotherapy-induced nausea and vomiting (CINV) claim 32 , cyclic vomiting syndrome claim 32 , postoperative nausea and ...

Подробнее

Номер записи: 95

03-01-2019 дата публикации

TREATMENT OF DEVELOPMENTAL SYNDROMES

Номер: US20190000993A1

Автор: DURING Matthew

Принадлежит:

A method of treating a developmental syndrome in a patient in need thereof includes applying ultrasound to a target location in the patient's brain to enhance permeability of the patient's blood brain barrier at the target location and administering to the patient a vector encoding BDNF for delivery of BDNF to the target location, wherein the method provides improvement in at least one symptom of the developmental syndrome. Also provided is a method of treating a developmental syndrome in a patient in need thereof that includes administering to the patient an effective amount of a vector including (i) a constitutive promoter operatively linked to nucleic acid encoding BDNF, and (ii) a regulatory sequence including an AGRP promoter operatively linked to an interference RNA sequence, wherein the regulatory sequence down regulates expression of BDNF in response to BDNF induced physiological changes, and the method provides improvement in at least one symptom of the developmental syndrome. 148-. (canceled)49. A method of treating a developmental syndrome in a patient in need thereof comprising:applying ultrasound to a target location in the patient's brain to enhance permeability of the patient's blood brain barrier at the target location;administering to the patient a vector encoding BDNF for delivery of BDNF to the target location, wherein the method provides improvement in at least one symptom of the developmental syndrome.50. The method according to claim 49 , wherein the ultrasound is administered to the target location in the patient's brain at a frequency ranging from 250 kHz to 10 MHz claim 49 , sonication duration ranging from 100 nanoseconds to 30 minutes claim 49 , with continuous wave or burst mode operation claim 49 , where the burst mode repetition varies from 0.01 Hz to 1 MHz.51. The method according to claim 49 , wherein the ultrasound is administered to the target location in the patient's brain at a frequency ranging from 20 kHz to 5 MHz claim 49 , and ...

Подробнее

Номер записи: 96

02-01-2020 дата публикации

DNA plasmids for the Fast Generation of Homologous Recombination Vectors For Cell Line Development

Номер: US20200002729A1

Автор: Oscar M. Perez-Leal

Принадлежит: Temple University of Commonwealth System of Higher Education

The present invention provides homologous recombination vectors to insert transgenic DNA in cells. These vectors shorten the production time and allow for easy generation of genetically modified cells. The invention allows the user to test multiple tags and to generate homozygous modified cell line using the homologous recombination vector. The invention can be used to generate knockout cells, to generate cell lines with knockin genes, to generate cell lines for drug screening against any target, to create transgenic animals, or in gene therapy.

Подробнее

Номер записи: 97

01-01-2015 дата публикации

Cyanocobalamin low viscosity aqueous formulations for intranasal delivery

Номер: US20150004198A1

Автор: Anthony P. Sileno, Peter C. Aprile, Steven C. Quay, Zenaida O. Go

Принадлежит: Par Pharmaceuticals Inc

A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin.

Подробнее

Номер записи: 98

03-01-2019 дата публикации

Dephosphorylated lysosomal storage disease proteins and methods of use thereof

Номер: US20190002852A1

Автор: Reinhard Gabathuler, Timothy Z. Vitalis

Принадлежит: Bioasis Technologies Inc

Provided are substantially dephosphorylated forms of lysosomal storage disease (LSD) proteins, including dephosphorylated forms of iduronate-2-sulfatase (IDS, or I2D) and iduronidase (IDU), having increased ability to traverse or penetrate the blood brain barrier (BBB) relative to phosphorylated forms of the protein, and p97 conjugates thereof. Also provided are compositions comprising such dephosphorylated LSD proteins and p97 conjugates, and methods of use thereof, for instance, to treat any one or more lysosomal storage diseases, such as Hunter Syndrome (or MPS Type II).

Подробнее

Номер записи: 99

27-01-2022 дата публикации

SYNERGISTIC COMPOSITION FOR MAINTENANCE OF HEALTHY BALANCE OF MICROFLORA

Номер: US20220023322A1

Автор: Bartell Ryan Daniel, Hollmaier Paige Nicole, Joyner Cheryce Francina, Koenig David William, Li Jingru, Peed Lindsay Adrienne, Vongsa Rebecca Ann

Принадлежит:

The present invention relates to compositions, particularly compositions useful in maintaining and supporting healthy microflora in the female urogenital tract which could lead to inhibition of vaginal infections, as well as methods of treating and preventing vaginal infections. Compositions useful in supporting healthy microflora, disclosed herein, generally comprise a therapeutic amount of a first saccharide and a therapeutic amount of a second saccharide or an organic acid. The saccharides may be, for example, a pentose, a disaccharide, a cyclodextrin, a pectic substance or a non-digestible polysaccharide. The organic acid may be, for example, malic acid. 120.-. (canceled)21. A method for maintaining or supporting a healthy microflora balance in the urogenital area of a patient in need thereof , the method comprising topically administering to the urogenital area of the patient a composition comprising a first therapeutic agent comprising D-Trehalose and a second therapeutic agent comprising pectin.22. The method of claim 21 , wherein the weight ratio of the first therapeutic and the second therapeutic agent is from about 1:1 to about 1:50.23. The method of claim 21 , wherein a total amount of the first therapeutic agent and the second therapeutic agent comprises less than about 10.0 wt/vol % of the composition.24. The method of claim 21 , wherein the first therapeutic agent comprises from about 0.1 to about 2.0 wt/vol % claim 21 , the second therapeutic agent comprises from about 0.1 to about 2.0 wt/vol %.25L. crispatusE. coli. The method of claim 21 , wherein the composition synergistically promotes the growth of relative to such that the therapeutic effect is greater than about 30.26Lactobacillus. The method of claim 21 , wherein administration of the composition increases growth or activity in vivo.27. A method for maintaining or supporting a healthy microflora balance in the urogenital area of a patient in need thereof claim 21 , the method comprising ...

Подробнее

Номер записи: 100

Настройки

Небесная энциклопедия

Мониторинг СМИ

Форма поиска